Estrada-Riega I, Vizzuett-Cienfuegos KA, Cruz-Vidaños JC, Ortega-Pérez AQ, García-Domínguez RI, Garduño-Alanís A

Language: Spanish
References: 20
Page: 202-205
PDF size: 132.37 Kb.

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a major cause of mortality and disability worldwide. In 2016, in Mexico the prevalence of T2DM was 9.4%. Actual treatment for T2DM there include: hypoglycemic agents, insulins, nutritional therapy, as well as nutritional supplements with potential therapeutic effects such as probiotics. Probiotics are live microorganisms that confer a health benefit when administered via enteral in adequate amounts. The use of probiotics can improve glucose metabolism when its administration is longer than 8 weeks and this includes multiple bacterial strains. Some of the mechanisms of probiotic’s therapeutic effect: the increase in the secretion of peptide 1 similar to glucagon from L-enteroendocrine cells, the improvement of carbohydrate metabolism, the decrease in glucotoxicity, and the increase in sensitivity to the insulin of the target cells. Some studies report significant clinical effects in reducing serum levels of: glycosylated hemoglobin (HbAc1), serum glucose, cholesterol and triglycerides, as well as reduction of adipose tissue. These beneficial effects support its use as an adjunctive nutritional treatment to the pharmacologic in the metabolic control of patients with T2DM. The objective of this work was to identify the metabolic benefits of the use of probiotics in glucemic control in patients with type 2 diabetes mellitus.

REFERENCES

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14(2): 88-98.

2. Amezcua-Macías A, Rodríguez-Weber F, Díaz-Greene E. Apego al tratamiento y control de los pacientes diabéticos en la comunidad. Med Int Mex. 2015; 31: 274-80.

3. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Diabetes Atlas, 2015. Disponible en: http://www. diabetesatlas.org.

4. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernandez-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017; 75(Suppl a): 4-12.

5. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2019. American Diabetes Association Diabetes Care. 2019; 42 (Suppl 1): S13-S28.

6. Cremon C, Barbaro MR, Ventura M, Barbara G. Pre- and probiotic overview. Curr Opin Pharmacol. 2018; 43: 87-92.

7. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017; 14(8): 491-502.

8. Ejtahed HS, Mohtadi-Nia J, Homayuni Rad A, Niafar M, Asghari Jafarabi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012; 28(5): 539-43.

9. Kasinska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes? a meta- analysis. Pol Arch Med Wewn. 2015; 125(11): 803-13.

10. Sabico S, Al-Mashharawi A, Al-Daghri NM, Yakout S, Alnaami AM, Alokail MS, et al. Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial. J Transl Med. 2017; 15(1): 1-9.

11. Zhang Q, Wu Y, Fei X. Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus? A meta-analysis of randomized controlled trials. Medicina (Kaunas). 2016; 52(1): 28-34.

12. I MM, Shahraki S, Ii D, Iii NR, Golpour S, Iii H, et al. Potential mechanisms linking probiotics to diabetes: a narrative review of the literature. Sao Paulo Med J. 2017; 135(2): 169-78.

13. Sun J, Buys NJ. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes? a meta-analysis of randomised placebo-controlled trials. Br J Nutr. 2016; 115(7): 1167-77.

14. Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG, de la Barca AM. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep. 2014; 4: 3814.

15. Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, et al. Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators, lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics Antimicrob Proteins. 2017; 9(1): 41-7.

16. Higashikawa F, Noda M, Awaya T, Danshiitsoodol N, Matoba Y, Kumagai T, et al. Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects? a randomized, double-blind, placebo-controlled clinical trial. Eur J Clin Nutr. 2016; 70(5): 582-7.

17. Balakumar M, Prabhu D, Sathishkumar C, Prabu P, et al. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet -fed C57BL/6J mice. Eur J Nutr. 2018; 57(1): 279-95.

18. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr. 2015; 33: 25.

19. Kassaian N, Aminorroaya A, Feizi A, Jafari P, Amini M. The effects of probiotic and synbiotic on lipid profiles in adults at risk of type 2 diabetes: a double-blind randomized controlled trial. Trial. 2017; 18 (1): 148.

20. Kassaian N, Feizi A, Aminorroaya A, Jafari P, Tejadabi Ebrahimi MT, Amini M. The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial. Acta Diabetol. 2018; 55(10): 1019-28.